Evaluation of an oral small-molecule glucagon-like peptide-1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: A dose-ranging, phase 2, randomized, placebo-controlled study
Amin NB, Frederich R, Tsamandouras N, et al.
Diabetes Obes Metab. Pub. online 16 Oct 2024.
Leggi